Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

By Rishika Sadam HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its ...

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core ...